Cantourage Group (HIGH) Q1 2026 TU earnings summary

Executive summary

• Profitability increased significantly in Q1 2026, driven by a focus on premium products and international expansion.

• Revenue grew 11.0% sequentially to EUR 20.6 million, with EBITDA reaching EUR 2.2 million and a margin of 10.6%.

• Strong financial position maintained, with a net cash position of EUR 8.8 million at quarter-end.

• Geographic diversification accelerated, with the UK now contributing 41.3% of revenue.

Financial highlights

• Revenue increased by 11.0% compared to Q4 2025, reaching EUR 20.6 million.

• EBITDA improved to EUR 2.2 million, with a margin of 10.6%.

• Net cash position stood at EUR 8.8 million at the end of Q1 2026.

Outlook and guidance

• Regulatory changes in Germany seen as an opportunity to expand market position.

• Continued investments in innovation, digitalization, and telemedicine platforms in Germany and the UK.

• Ongoing development of new product formats to address evolving patient needs.